Education
About Us
Working with TipRanks
Follow Us
Standard Biotools Inc (LAB)
:LAB
Top Page
Standard BioTools
(NASDAQ:LAB)39Underperform
Positive Factors
Operational Improvements
Despite headwinds, LAB management continues to make progress on underlying operations and is targeting improvements.
Strategic Initiatives
The merger with SLGC nearly doubles LAB's revenues, expands the TAM & strengthens the balance sheet.
Negative Factors
Financial Guidance
FY25 guidance was disappointing at $165M-$175M vs. consensus of $186.9M or a -3% decline at the midpoint.
Revenue Miss
2Q revenue missed consensus ($37.2M < $48.2M), a notable miss after a solid 1Q where management reiterated FY'24 guidance.
Standard BioTools (LAB) vs. S&P 500 (SPY)
Market Cap
$402.04M
Dividend YieldN/A
Average Volume (3M)2.32M
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth48.23%
EPS Growth25.93%
CountryUS
Employees539
SectorHealthcare
Sector Strength74
IndustryMedical Diagnostics & Screening
Share Statistics
EPS (TTM)-0.55
Shares Outstanding372,258,800
10 Day Avg. Volume3,305,177
30 Day Avg. Volume2,319,813
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.77
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.50Price Target Upside131.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Standard BioTools Business Overview & Revenue Model
Company DescriptionStandard BioTools (formerly known as Fluidigm Corporation) operates in the life sciences sector, focusing on providing innovative tools and technologies for biological research and development. The company's core products include advanced analytical instruments, microfluidic systems, and consumables that facilitate high-throughput genomics, proteomics, and single-cell analysis. These products support various applications in research laboratories, pharmaceutical companies, and academic institutions, aiding in the exploration of complex biological systems and the advancement of precision medicine.
How the Company Makes MoneyStandard BioTools generates revenue primarily through the sale of its analytical instruments and consumables. The company offers a range of products that cater to different aspects of biological research, including genomics and proteomics. Revenue streams include direct sales to research institutions and laboratories, as well as partnerships and collaborations with pharmaceutical companies that utilize its technology for drug discovery and development. Additionally, the company may earn from service agreements, training, and customer support related to its products. Significant factors contributing to its earnings include the growing demand for advanced research tools in the life sciences sector and its ability to innovate and create technologies that address emerging research needs.
Standard BioTools Financial Statement Overview
Summary
Standard BioTools shows strong revenue growth of 46.6% year-over-year but struggles with profitability, as indicated by a negative net profit margin of -79.9% and negative cash flows. The company has a low debt-to-equity ratio, which is positive, but ongoing net losses highlight the need for operational improvements.Income Statement
The income statement reveals a challenging financial position for Standard BioTools. The TTM (Trailing-Twelve-Months) gross profit margin stands at approximately 48.6%, a reasonable figure indicating ability to cover costs, but the net profit margin is severely negative, at about -79.9%, driven by substantial net losses. The revenue growth rate from the previous year to the TTM period is 46.6%, suggesting strong sales growth, but the company is grappling with profitability issues as indicated by negative EBIT and EBITDA margins.42
Neutral
Balance Sheet
The balance sheet shows a mixed financial health. The debt-to-equity ratio is approximately 0.18, indicating a relatively low level of leverage, which is a strength. However, the return on equity (ROE) is not applicable due to negative net income and previous negative equity figures. The equity ratio is around 71.8%, reflecting a strong equity base relative to total assets, which is positive for stability.55
Neutral
Cash Flow
Cash flow analysis indicates significant challenges. Free cash flow remains negative, and the free cash flow growth rate is negative, worsening from the previous period. The operating cash flow to net income ratio is negative, highlighting issues in converting sales into cash flow. This suggests potential liquidity and operational challenges.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 155.90M | 106.34M | 97.95M | 130.58M | 138.14M | 117.24M | Gross Profit |
| 75.71M | 50.45M | 37.05M | 69.37M | 83.33M | 64.28M | EBIT |
| -127.35M | -76.60M | -116.20M | -67.46M | -51.04M | -51.84M | EBITDA |
| -116.57M | -54.46M | -173.57M | -43.77M | -34.60M | -46.62M | Net Income Common Stockholders |
| -124.59M | -74.66M | -190.10M | -59.24M | -53.02M | -64.79M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 95.40M | 114.89M | 165.78M | 28.45M | 68.52M | 58.64M | Total Assets |
| 303.65M | 323.07M | 390.31M | 275.21M | 324.76M | 264.81M | Total Debt |
| 172.06M | 98.21M | 102.66M | 111.65M | 95.38M | 59.98M | Net Debt |
| 76.66M | 46.51M | 21.35M | 83.20M | 26.86M | 38.32M | Total Liabilities |
| 231.53M | 159.87M | 471.78M | 180.62M | 185.71M | 111.20M | Stockholders Equity |
| 72.12M | 163.20M | -81.47M | 94.60M | 139.05M | 153.61M |
| Cash Flow | Free Cash Flow | ||||
| -148.51M | -46.12M | -93.19M | -57.33M | -28.13M | -37.74M | Operating Cash Flow |
| -143.46M | -43.29M | -89.37M | -44.06M | -15.42M | -35.21M | Investing Cash Flow |
| 324.33M | 20.24M | -88.13M | -11.95M | 39.98M | -39.30M | Financing Cash Flow |
| -49.10M | -6.81M | 230.76M | 15.96M | 20.86M | 2.79M |
Standard BioTools Technical Analysis
Negative
1.08
Price Trends
1.52
Negative
1.70
Negative
1.86
Negative
Market Momentum
-0.12
Negative
36.93
Neutral
38.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Negative. The current price of 1.08 is below the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.52, and below the 200-day MA of 1.86, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 36.93 is Neutral, neither overbought nor oversold. The STOCH value of 38.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LAB.
Standard BioTools Risk Analysis
Standard BioTools disclosed 63 risk factors in its most recent earnings report. Standard BioTools reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Standard BioTools Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $198.74B | 32.15 | 13.15% | 0.29% | 0.05% | 6.87% | |
68 Neutral | $34.75B | 29.12 | 20.61% | 0.75% | -3.00% | 3.67% | |
65 Neutral | $146.68B | 40.10 | 7.57% | 0.51% | -13.50% | -17.25% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
49 Neutral | $6.96B | ― | -24.09% | ― | -3.92% | -202.80% | |
49 Neutral | $13.62B | ― | -30.11% | ― | -2.93% | -4.69% | |
39 Underperform | $402.04M | ― | -43.75% | ― | 48.23% | 25.93% |
* Healthcare Sector Average
Performance Comparison
LAB
Standard BioTools
1.08
-1.60
-59.70%
A
Agilent
121.90
-24.92
-16.97%
BIO
Bio-Rad Laboratories
247.76
-89.46
-26.53%
DHR
Danaher
205.23
-46.78
-18.56%
ILMN
Illumina
85.97
-43.00
-33.34%
TMO
Thermo Fisher
526.80
-68.83
-11.56%
Standard BioTools Earnings Call Summary
Earnings Call Date: Feb 26, 2025 | % Change Since: -7.69% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Neutral
Despite the successful realization of cost synergies and a strong balance sheet, the company faced significant revenue declines and market challenges, including reduced instrument sales and potential impacts from NIH funding and tariffs. The growth in consumables and strategic initiatives in proteomics provide optimism, but the current market and economic environment pose challenges.Highlights
Cost Synergies and Operational Improvements
Operationalized $80 million in cost synergies a year ahead of plan, with an additional $10 million in cost reductions. Achieved a 22% year-over-year reduction in non-GAAP operating expenses and a 33% improvement in adjusted EBITDA.
Strong Balance Sheet
Nearly $300 million in cash with substantially no debt, providing flexibility to execute strategic plans and potential acquisitions.
Consumables Growth
Consumables revenue grew 10% in the fourth quarter and 18% for the full year 2024, driven by SomaScan authorized sites and the Illumina early access program.
Proteomics and Illumina Partnership
SomaScan platform is positioned as a leader in plasma proteomics, with a strategic partnership with Illumina, unlocking large-scale protein analysis opportunities. Expecting a significant market opportunity, estimated at $1 billion.
Lowlights
Revenue Decline
Fourth quarter and full year 2024 revenue declined 9% year-over-year, impacted by softness in instruments and services.
Instrument Sales Decline
Instrument sales were down 25% in Q4 and 27% for the year, primarily due to capital spending constraints.
Market and Economic Challenges
Anticipated reduction in NIH spending and academic revenue, potential impacts from tariffs, and cautious spending in biopharma and academia.
Service Revenue Decline
Lab Services sales were down 18% in Q4 and 21% for the year, affected by high customer concentration and variability in demand from large pharma accounts.
Company Guidance
During the fourth quarter and full year 2024 financial results call, Standard BioTools provided a comprehensive overview of their performance and outlined guidance for 2025. The company reported $46.7 million in revenue for the fourth quarter and $175.1 million for the full year, both reflecting a 9% year-over-year decline. Despite the revenue drop, the company achieved a 33% improvement in adjusted EBITDA compared to 2023, driven by $80 million in cost synergies operationalized through the merger with SomaLogic. Looking forward, Standard BioTools anticipates 2025 organic revenue between $165 million and $175 million, an approximate 3% decline at the midpoint, factoring in anticipated headwinds such as a mid-teens percentage decline in Americas academic revenue due to potential NIH funding cuts. The company maintains a strong balance sheet with nearly $300 million in cash, positioning it to execute strategic plans and fund potential acquisitions. They remain on track to reach adjusted EBITDA breakeven in 2026, even as they navigate macroeconomic challenges and evolving market conditions.Standard BioTools Corporate Events
Business Operations and StrategyFinancial Disclosures
Standard BioTools Reports 2024 Financial Results and Strategic Outlook
Neutral
Feb 26, 2025
Standard BioTools reported its financial results for the fourth quarter and full year 2024, highlighting a pro forma combined revenue of $175.1 million, a 9% decrease year-over-year. The company achieved significant operational cost reductions totaling $90 million in synergies over 12 months, and improved its adjusted EBITDA by 33% year-over-year. Despite a net loss of $34.1 million in Q4 2024, the company has a strong balance sheet with $295 million in cash and no material debt, positioning it for future growth and strategic acquisitions. Looking forward, Standard BioTools aims to focus on higher-margin offerings and capitalize on a billion-dollar opportunity in the proteomics market with its upcoming NGS-based solution in partnership with Illumina.
Business Operations and StrategyFinancial Disclosures
Standard BioTools Reports 2024 Revenue Achievements and Plans
Positive
Jan 13, 2025
Standard BioTools announced preliminary, unaudited revenue results for the fourth quarter and full year 2024, reporting approximately $46.5 million for the quarter and $174 million for the year. Despite industry-wide challenges, the company reached the upper end of its revised forecast and has been implementing the Standard BioTools Business Systems to reduce operating expenses. The company plans to further enhance efficiencies and shift towards high-margin markets in 2025, aiming to deliver long-term value to shareholders and customers.
Executive/Board Changes
Standard BioTools Announces CCO Jeremy Davis’s Departure
Neutral
Jan 10, 2025
Standard BioTools Inc. announced that their Chief Commercial Officer, Jeremy Davis, will step down from his position effective February 1, 2025. The company will enter into a severance agreement with Davis, which includes a continuation of salary payments totaling $441,000 over a year, a bonus for the 2024 fiscal year, a pro-rated target bonus, payment of COBRA premiums, and full vesting of equity awards, indicating a structured transition plan for the leadership change.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.